Esperion Therapeutics Projects 2026 Operating Expenses Between $225M and $255M
ESPR has more than doubled off its 52-week low of $0.693.
Summary
Esperion Therapeutics has provided its operating expense guidance for 2026, projecting costs to be in the range of $225 million to $255 million. This forward-looking financial information is material for investors to update their financial models and assess the company's future profitability and cash burn. While the timeline shows a recent acquisition of Corstasis Therapeutics, this expense guidance is new information that will be factored into the company's overall financial outlook. Traders will be evaluating this guidance against analyst consensus and the potential impact on the company's path to profitability, especially in light of recent M&A activity.
At the time of this announcement, ESPR was trading at $3.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $726.8M. The 52-week trading range was $0.69 to $4.18. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.